This article is more than 5 years old. Information may no longer be current.
EyeGate receives grant to continue development of ocular bandage film
Click Here to Manage Email Alerts
Jade Therapeutics, a subsidiary of EyeGate Pharmaceuticals, received $448,185 in funding from the U.S. Army Medical Research and Materiel Command for a second year, EyeGate announced.
The funding will be used to continue developing a proprietary thiolated hyaluronic acid (CMHA-S) product, which is under study for use as an ocular bandage film, and brings the total funding Jade has received from the U.S. Army’s Small Business Innovation Research program to $1.25 million, according to a press release.
“We are extremely grateful to the USAMRMC and Department of Defense for this grant, which provides non-dilutive funding that will allow us to continue our preclinical work to assess the potential of CMHA-S film as a treatment for ocular surface injuries,” Barbara Wirostko, MD, EyeGate’s chief medical officer, said in the release. “Our novel, polymer-based room temperature stable ocular surface bandage can be applied immediately at the time of eye injury to treat both acute and chronic ocular surface conditions, with the potential to greatly reduce post-incident complications which could lead to permanent eye injury or blindness.”
The films have potential for use as a treatment for traumatic eye injuries as well as a bandage for ocular surface defects, inflammation and corneal damage in both military and civilian populations, according to Wirostko.